Loading...
Loading...
- Regeneron Pharmaceuticals Inc REGN earned $12.56 per share for Q4 FY22, down 46% Y/Y, beating the $10.03 Street estimate.
- Revenues decreased 31% Y/Y to $3.41 billion; excluding REGEN-COV and Ronapreve, revenues increased 14%, slightly ahead of the analyst consensus of $3.13 billion.
- The company recorded no sales in the quarter for its COVID-19 antibody drug due to the FDA's decision to limit its use in January last year in all states because of a lack of effectiveness against the omicron variant.
- Eylea U.S. net sales decreased by 3% to $1.5 billion due to a short-term shift to off-label use of compounded bevacizumab and a temporary closing of a not-for-profit fund providing patient co-pay assistance.
- Volumes of U.S. EYLEA in Q4 increased compared to a year ago.
- Related: UK Drug Regulator Warns Of Severe Eye Reactions Associated With Sanofi/Regeneron's Dupixent.
- The operating margin compressed from 53.3% to 33.6%.
- The company announced a new $3-billion share repurchase program authorized in January 2023.
- The company's net income fell to $1.2 billion, or $10.50 per share, in the quarter that ended Dec. 31, from $2.23 billion, or $19.69 per share, a year earlier.
- Price Action: REGN shares closed at $751.20 on Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in